

Relapse Prevention: Long-Acting Atypical Antipsychotics (NIH 1 U01 MH070016-01A2)

PI: Daniel R. Wilson, M.D., Ph.D.

This is a multicenter, randomized, open, effectiveness trial for patients with schizophrenia and schizoaffective disorder whose clinicians are considering long-term treatment with a second-generation antipsychotic medication.

To be eligible, you must also:

- Must be 19-75 years of age
- Had an exacerbation of your illness within the last 6 months

Contact Coordinator: Kim at 345-8828 x22